P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab
Authors:
Open Access
- 23 January 2009
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 16 (6) , 498-507
Abstract
Cetuximab (Erbitux) is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody whose activity is related to the inhibition of EGFR downstream signaling pathways. P53 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) have been reported to control the functionality of PI3K/AKT signaling. In this study we evaluated whether reintroducing P53 using non-viral gene transfer enhances PTEN-mediated inhibition of PI3K/AKT signaling by cetuximab in PC3 prostate adenocarcinoma cell line bearing p53 and pten mutations. Signaling phosphoproteins expression was analyzed using Bio-Plex phosphoprotein array and western blot. Apoptosis induction was evaluated from BAX expression, caspase-3 activation and DNA fragmentation analyses. The results presented show that p53 and pten gene transfer additionally mediated cell growth inhibition and apoptosis induction by restoral of signaling functionality, which enabled the control of PI3K/AKT and MAPKinase signaling pathways by cetuximab in PC3 cells. These results highlight the interest of the analysis of signaling phosphoproteins expression as molecular predictive markers for response to cetuximab and show that p53 and pten mutations could be key determinants of cell response to cetuximab through the functional impact of these mutations on cell signaling.Keywords
This publication has 28 references indexed in Scilit:
- RETRACTED: Theaflavins induced apoptosis of LNCaP cells is mediated through induction of p53, down-regulation of NF-kappa B and mitogen-activated protein kinases pathwaysLife Sciences, 2007
- p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non–Small Cell Lung CancerCancer Research, 2007
- EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancerBiochemical Pharmacology, 2005
- Review of epidermal growth factor receptor biologyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7Seminars in Cancer Biology, 2003
- p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomasGenes & Development, 2002
- The EGFR family and its ligands in human cancerEuropean Journal of Cancer, 2001
- The EGF receptor family as targets for cancer therapyOncogene, 2000
- The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy, 1996